Bluejay Diagnostics Secures US Manufacturing Partnership for Symphony Platform
BJDX has more than doubled off its 52-week low of $1.623.
Summary
Bluejay Diagnostics announced a strategic partnership with Argonaut Manufacturing Services to establish U.S.-based manufacturing capabilities for its investigational Symphony™ platform. This move aims to strengthen commercial infrastructure, enhance supply chain resilience, and mitigate risks from overseas manufacturing. The partnership is a positive operational step towards future commercialization for Bluejay, which reported a critical "going concern" warning in its May 7th 10-Q, with cash projected to last only through Q3 2026 and a need for $20 million by 2027. The company's SYMON-II study is the pivotal trial intended to support a 510(k) application to the FDA.
At the time of this announcement, BJDX was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.62 to $16.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.